193 related articles for article (PubMed ID: 38199985)
1. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease.
Maas-Bauer K; Stell AV; Yan KL; de Vega E; Vinnakota JM; Unger S; Núñez N; Norona J; Talvard-Balland N; Koßmann S; Schwan C; Miething C; Martens US; Shoumariyeh K; Nestor RP; Duquesne S; Hanke K; Rackiewicz M; Hu Z; El Khawanky N; Taromi S; Andrlova H; Faraidun H; Walter S; Pfeifer D; Follo M; Waldschmidt J; Melchinger W; Rassner M; Wehr C; Schmitt-Graeff A; Halbach S; Liao J; Häcker G; Brummer T; Dengjel J; Andrieux G; Grosse R; Tugues S; Blazar BR; Becher B; Boerries M; Zeiser R
Nat Commun; 2024 Jan; 15(1):446. PubMed ID: 38199985
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of IL-1 Receptor-Associated Kinase 1 Decreases Murine Acute Graft-versus-Host Disease While Preserving the Graft-versus-Lymphoma Effect.
Gao J; Xu Y; Ma S; Liang Y; Liu C; Shen J; Sun Z; Niu M; Xu K; Pan B
Transplant Cell Ther; 2022 Mar; 28(3):134.e1-134.e10. PubMed ID: 34896653
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
Abedin SM; Hamadani M
Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
[TBL] [Abstract][Full Text] [Related]
8. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
Yao Y; Wang L; Zhou J; Zhang X
J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization.
Liu X; Su Y; Sun X; Fu H; Huang Q; Chen Q; Mo X; Lv M; Kong Y; Xu L; Huang X; Zhang X
Sci China Life Sci; 2020 Nov; 63(11):1744-1754. PubMed ID: 32382983
[TBL] [Abstract][Full Text] [Related]
10. Kinase Inhibition as Treatment for Acute and Chronic Graft-
Braun LM; Zeiser R
Front Immunol; 2021; 12():760199. PubMed ID: 34868001
[TBL] [Abstract][Full Text] [Related]
11. Daclizumab for children with corticosteroid refractory graft-versus-host disease.
Teachey DT; Bickert B; Bunin N
Bone Marrow Transplant; 2006 Jan; 37(1):95-9. PubMed ID: 16247417
[TBL] [Abstract][Full Text] [Related]
12. Rho Kinase Type 1 (ROCK1) Promotes Lipopolysaccharide-induced Inflammation in Corneal Epithelial Cells by Activating Toll-Like Receptor 4 (TLR4)-Mediated Signaling.
Gong J; Guan L; Tian P; Li C; Zhang Y
Med Sci Monit; 2018 May; 24():3514-3523. PubMed ID: 29804125
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.
De Togni E; Cole O; Abboud R
Front Immunol; 2024; 15():1304065. PubMed ID: 38380328
[TBL] [Abstract][Full Text] [Related]
14. The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.
Schroeder MA; Choi J; Staser K; DiPersio JF
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1125-1134. PubMed ID: 29289756
[TBL] [Abstract][Full Text] [Related]
15. The effects of knockdown of rho-associated kinase 1 and zipper-interacting protein kinase on gene expression and function in cultured human arterial smooth muscle cells.
Deng JT; Wang XL; Chen YX; O'Brien ER; Gui Y; Walsh MP
PLoS One; 2015; 10(2):e0116969. PubMed ID: 25723491
[TBL] [Abstract][Full Text] [Related]
16. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness.
Mohty M; Holler E; Jagasia M; Jenq R; Malard F; Martin P; Socié G; Zeiser R
Blood; 2020 Oct; 136(17):1903-1906. PubMed ID: 32756949
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia.
Mathew NR; Vinnakota JM; Apostolova P; Erny D; Hamarsheh S; Andrieux G; Kim JS; Hanke K; Goldmann T; Chappell-Maor L; El-Khawanky N; Ihorst G; Schmidt D; Duyster J; Finke J; Blank T; Boerries M; Blazar BR; Jung S; Prinz M; Zeiser R
J Clin Invest; 2020 Mar; 130(3):1315-1329. PubMed ID: 31846439
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
[TBL] [Abstract][Full Text] [Related]
19. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
[TBL] [Abstract][Full Text] [Related]
20. Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation.
Yang S; Wei Y; Sun R; Lu W; Lv H; Xiao X; Cao Y; Jin X; Zhao M
Cytotherapy; 2020 Dec; 22(12):718-733. PubMed ID: 32811747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
